JP2020516601A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516601A5
JP2020516601A5 JP2019554737A JP2019554737A JP2020516601A5 JP 2020516601 A5 JP2020516601 A5 JP 2020516601A5 JP 2019554737 A JP2019554737 A JP 2019554737A JP 2019554737 A JP2019554737 A JP 2019554737A JP 2020516601 A5 JP2020516601 A5 JP 2020516601A5
Authority
JP
Japan
Prior art keywords
antigen
tumor
protein
arenavirus
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/058900 external-priority patent/WO2018185307A1/en
Publication of JP2020516601A publication Critical patent/JP2020516601A/ja
Publication of JP2020516601A5 publication Critical patent/JP2020516601A5/ja
Pending legal-status Critical Current

Links

JP2019554737A 2017-04-07 2018-04-06 固形腫瘍を治療するためのアレナウイルス粒子 Pending JP2020516601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483067P 2017-04-07 2017-04-07
US62/483,067 2017-04-07
PCT/EP2018/058900 WO2018185307A1 (en) 2017-04-07 2018-04-06 Arenavirus particles to treat solid tumors

Publications (2)

Publication Number Publication Date
JP2020516601A JP2020516601A (ja) 2020-06-11
JP2020516601A5 true JP2020516601A5 (enExample) 2021-05-20

Family

ID=62025795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554737A Pending JP2020516601A (ja) 2017-04-07 2018-04-06 固形腫瘍を治療するためのアレナウイルス粒子

Country Status (7)

Country Link
US (1) US20200113995A1 (enExample)
EP (1) EP3606549A1 (enExample)
JP (1) JP2020516601A (enExample)
CN (1) CN110719788A (enExample)
AU (1) AU2018247958A1 (enExample)
CA (1) CA3058539A1 (enExample)
WO (1) WO2018185307A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
IL298420A (en) * 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors
MX2023011054A (es) 2021-03-23 2023-11-22 Hookipa Biotech Gmbh Arenavirus utilizados en tratamientos del cáncer de próstata.
EP4337320A1 (en) * 2021-05-13 2024-03-20 Hookipa Biotech GmbH Arenaviruses as vectors
US20250073324A1 (en) 2021-11-08 2025-03-06 Hookipa Biotech Gmbh Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
EP4475879A1 (en) 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
AR128799A1 (es) * 2022-03-16 2024-06-12 Boehringer Ingelheim Int Antígenos tumorales, compuestos que comprenden los antígenos tumorales y usos de los mismos
CN115192709B (zh) * 2022-05-12 2023-07-21 黄淮学院 O-GlcNAc糖基转移酶抑制剂在制备抑制精子发生的药物中的用途
CN116218681B (zh) * 2022-08-02 2025-11-11 汕头大学 三角褐指藻钙网蛋白基因过表达突变株的构建方法
WO2025101837A1 (en) * 2023-11-10 2025-05-15 Eccletech Llc Biological devices and methods of using the same for detection of different types of cancer
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA2499837C (en) * 2002-10-03 2013-12-03 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
CN103993012B (zh) * 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
AU2015222685A1 (en) * 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
ES2811093T3 (es) * 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP3373959B1 (en) * 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
IL262963B2 (en) * 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
CN110167586B (zh) * 2016-11-04 2024-01-30 霍欧奇帕生物科技有限公司 作为癌症疫苗的复制-缺陷型沙粒病毒颗粒和三-节段沙粒病毒颗粒

Similar Documents

Publication Publication Date Title
JP2023500928A5 (enExample)
JP2018533604A5 (enExample)
JP2019533690A5 (enExample)
HRP20221167T1 (hr) Čestice arenavirusa kao cjepiva protiv raka
JP2012500652A5 (enExample)
JP2023029898A5 (enExample)
Shirbaghaee et al. Different applications of virus‐like particles in biology and medicine: vaccination and delivery systems
Flingai et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants
Andrew et al. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus
JP7783631B2 (ja) ベクターとしてのアレナウイルス
JP6219849B2 (ja) 発癌性ウイルスポリペプチド陽性腫瘍治療用ポリヌクレオチド
WO2018185307A1 (en) Arenavirus particles to treat solid tumors
BR112020003007A2 (pt) modificação de células t
US20190000943A1 (en) Aav6 vectors for immunotherapy
Cubillos-Zapata et al. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo
AU2024265451A1 (en) Antigen-specific physiologic dendritic cells for vaccination
AR132582A1 (es) Método para inducir una respuesta inmunitaria
Wang et al. Development of a novel PCV2 and PCV3 vaccine using virus-like vesicles incorporating Venezuelan equine encephalomyelitis virus-containing vesicular stomatitis virus glycoprotein
RU2015121429A (ru) Химерные антигены для вакцины против вируса гепатита с
Sherritt et al. Effect of pre‐existing cytotoxic T lymphocytes on therapeutic vaccines
US12558417B2 (en) Hepatitis A virus preparation method and hepatitis A virus prepared according to method
US20140286978A1 (en) Cytotoxic t lymphocyte inducer
US20240245765A1 (en) Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines
KR20260010716A (ko) 요법용 항원-특이적 생리학적 수지상 세포
Orchard et al. Interleukin-2 secretion by transduced and unselected BDL-2 lymphoma results in increased survival in mice with previously established disseminated disease